Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in IVB stage, recurrent or persistent cervical squamous cell carcinoma
NCT06781073Phase 3Completed
- Start
- Jul 2017
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cervical squamous cell carcinoma (CSCC) comparing Nimotuzumab + TP with Placebo + TP (2 arms). Primary endpoint: Overall Survival at 46 months. Started Jul 2017; status: completed.
02
Drugs
nimotuzumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT06781073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781073.